Viewing Study NCT04248569

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:04 PM
Ignite Modification Date: 2026-02-22 @ 4:53 PM
Study NCT ID: NCT04248569
Status: RECRUITING
Last Update Posted: 2025-12-03
First Post: 2020-01-28
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Fibrolamellar Hepatocellular Carcinoma (FLC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None DNAJB1-PRKACA Peptide Vaccine View
None Nivolumab View
None Ipilimumab View
None Anti-PD-1 (receptor blocking antibody) View
None Anti-CTLA-4 (receptor blocking antibody) View
None Neoantigen Vaccines View
None Cancer Vaccines View
None Immunotherapy View
None Fibrolamellar Hepatocellular Cancer (FLC) View